Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
The Efficacy Of Anakinra Compared To Standard Care Of Treatment For Covid-19: A Metaanalysis, Hamna Malik, Hira Bint Abdul Jabbar, Farah Latif, Azza Sarfraz, Zouina Sarfraz, Muzna Sarfraz
The Efficacy Of Anakinra Compared To Standard Care Of Treatment For Covid-19: A Metaanalysis, Hamna Malik, Hira Bint Abdul Jabbar, Farah Latif, Azza Sarfraz, Zouina Sarfraz, Muzna Sarfraz
Turkish Journal of Medical Sciences
Background/aim: As SARS-CoV-2 continues to spread worldwide, this study brings to light the link that anakinra, a recombinant IL-1 receptor antagonist, has in averting grave clinical outcomes. The objectives of this meta-analysis are to investigate the effects of anakinra in interventional groups compared to control/standard of care groups on mortality along with the provision of a prevalence estimate of the variables associated with death (C-reactive protein-CRP, ferritin, acute respiratory distress syndrome-ARDS). Materials and methods: According to the PRISMA 2020 statement guidelines, a systematic search was conducted from December 19, 2020, until December 10, 2021, with keywords including COVID-19, coronavirus, SARS-CoV-2, …
Comparison Of Anakinra And Tocilizumab In Management Of Severe Covid-19: A Retrospective Cohort Study, Orhan Küçükşahi̇n, Abdulsamet Erden, Özlem Karakaş, Serdar Can Güven, Berkan Armağan, Enes Seyda Şahi̇ner, Osman İnan, Ali̇ Can Kurti̇pek, Emi̇n Gemci̇oğlu, Selma Karaahmetoğlu, Sema Turan, Seval İzdeş, Deni̇z Erdem, Adalet Aypak, Müge Ayhan
Comparison Of Anakinra And Tocilizumab In Management Of Severe Covid-19: A Retrospective Cohort Study, Orhan Küçükşahi̇n, Abdulsamet Erden, Özlem Karakaş, Serdar Can Güven, Berkan Armağan, Enes Seyda Şahi̇ner, Osman İnan, Ali̇ Can Kurti̇pek, Emi̇n Gemci̇oğlu, Selma Karaahmetoğlu, Sema Turan, Seval İzdeş, Deni̇z Erdem, Adalet Aypak, Müge Ayhan
Turkish Journal of Medical Sciences
Background/aim: Studies regarding effectiveness of anakinra and tocilizumab treatments in coronavirus disease 2019 (COVID-19) have contradictory results. Furthermore, there is scarce comparative data regarding superiority of any agent. To further elucidate any superiority between these two agents, we retrospectively investigated and compared outcomes in hospitalized COVID-19 patients of our inpatient cohort who received anakinra or tocilizumab. Materials and methods: This study was designed as a single-center, retrospective, cross-sectional cohort study. Hospitalized patients with confirmed diagnosis of COVID-19 who had Brescia-COVID respiratory severity scale score ?3 and hyperinflammation (defined as elevation of C reactive protein ?50 g/L or ferritin ?700 ng/mL) …